Canada Post Corp Registered Pension Plan Has $13.91 Million Position in Zoetis Inc. $ZTS

Canada Post Corp Registered Pension Plan raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 22.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 110,569 shares of the company’s stock after acquiring an additional 20,379 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Zoetis were worth $13,912,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ZTS. Global Wealth Strategies & Associates bought a new stake in Zoetis in the fourth quarter worth $25,000. Lodestone Wealth Management LLC bought a new stake in Zoetis in the fourth quarter worth $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis in the third quarter worth $31,000. Holos Integrated Wealth LLC bought a new stake in Zoetis in the fourth quarter worth $32,000. Finally, Board of the Pension Protection Fund bought a new stake in Zoetis during the fourth quarter valued at about $38,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Zoetis news, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Frank A. Damelio acquired 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 11,650 shares of company stock valued at $886,384 in the last three months. 0.22% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Citigroup assumed coverage on shares of Zoetis in a report on Wednesday, April 15th. They set a “buy” rating and a $145.00 price target for the company. Piper Sandler reiterated a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. Bank of America increased their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $137.50.

Zoetis Price Performance

Shares of ZTS stock opened at $74.11 on Friday. The firm’s 50 day moving average price is $112.28 and its two-hundred day moving average price is $120.94. The stock has a market cap of $31.07 billion, a PE ratio of 12.29, a PEG ratio of 1.21 and a beta of 0.87. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $172.23. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.91 EPS for the current year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.